Cellular soldiers created using the body’s own defenses can track down and kill escaping cancer cells during surgeries, preventing metastasis and saving lives, a Vanderbilt University biomedical engineer has discovered, particularly in cases of triple negative breast cancer.

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

The Vanderbilt Center for Immunobiology has relaunched its mission with a greater focus on human immunology, an endeavor supported by additional researchers, more funding support and designation as a Center of Excellence.

Vanderbilt-Ingram Cancer Center scientists have discovered a role for a tumor suppressor protein in skin wound healing.

A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.

The U.S. Preventive Services Task Force (USPSTF) guidelines that determine which smokers qualify for CT scans exclude significant numbers of African Americans who develop lung cancer, a health disparity that merits modifications to lung cancer screening criteria, according to a study from Vanderbilt researchers.

Larry Marnett and colleagues have developed what may become the first agent for targeted PET imaging of cancer tissues, such as ovarian cancer, that express high levels of the COX-1 enzyme.

Vanderbilt University researchers have discovered how a protein pump distinguishes between chemicals that it will expel from a cell and inhibitors that block its action - findings that could guide the development of more efficient inhibitors to prevent cancer cell resistance to chemotherapy.

A recent study suggests that blocking the MYC protein could be “unexpectedly effective” in treating malignant rhabdoid tumor (MRT) is one of the most aggressive and lethal childhood cancers.

The 20th Annual Scientific Retreat will be held Wednesday, May 1, 8:30 a.m.